Skip to main content

Advertisement

Log in

A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia

Investigational New Drugs Aims and scope Submit manuscript

Summary

Background: Based on evidence of activity in epithelial tumors in preclinical and Phase I studies, its novel mechanism of action, and its tolerability we undertook a study of bortezomib [PS-341], a reversible proteasome inhibitor, for patients with advanced or metastatic urothelial cancer.

Patients and methods: Patients with advanced or metastatic unresectable urothelial carcinoma were enrolled onto this multicenter, phase II trial. Patients with measurable disease were treated with bortezomib 1.3 mg/m2/day (twice weekly for 2 weeks out of 3) by intravenous infusion on days 1, 4, 8, and 11 every 21 days. A two stage phase II design was used.

Results: Twenty-one patients were enrolled and twenty were eligible and received treatment. Eighty-five percent of patients had previous chemotherapy regimens. No objective responses were observed, median time-to-progression was 8.1 weeks (95% confidence interval [CI] 6.4 to 9), and median overall survival is estimated to be 15 weeks (95% CI 3.6 - NA). A total of 15 patients experienced a grade 3-4 adverse event. The most common were alkaline phosphatase (20% patients), lymphopenia (20% patients), myalgia (15% patients), dyspnea (15% patients) and thrombosis/embolism (15% patients).

Conclusion: Single-agent bortezomib is an ineffective treatment for progressive-cisplatin-refractory urothelial carcinoma and should not be considered for future clinical trials in this population of patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Jemal A, Murray T, Ward E et al (2005) Cancer statistics, 2005. CA Cancer J Clin 55(1):10–30

    Article  PubMed  Google Scholar 

  2. von der Maase H, Hansen SW, Roberts JT et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18(17):3068–3077

    PubMed  CAS  Google Scholar 

  3. De Mulder PH, Theodore C, Sella A et al (2000) Phase II EORTC trial with 5-fluorouracil, cisplatin and interferon-alpha as second-line treatment of advanced transitional cell cancer of the urothelial tract. Ann Oncol 11(11):1391–1394

    Article  PubMed  CAS  Google Scholar 

  4. Dreicer R, Manola J, Schneider DJ et al (2003) Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group. Cancer 97(11):2743–2747

    Article  PubMed  CAS  Google Scholar 

  5. Roth BJ, Manola J, Dreicer R, Graham D, Wilding G (2002) Piritrexim in advanced, refractory carcinoma of the urothelium (E3896): a phase II trial of the Eastern Cooperative Oncology Group. Invest New Drugs 20(4):425–429

    Article  PubMed  CAS  Google Scholar 

  6. Sweeney CJ, Williams SD, Finch DE et al (1999) A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium. Cancer 86(3):514–518

    Google Scholar 

  7. Winquist E, Vokes E, Moore MJ, Schumm LP, Hoving K, Stadler WM (2005) A phase II study of oxaliplatin in urothelial cancer. Urol Oncol 23(3):150–154

    PubMed  CAS  Google Scholar 

  8. Hideshima T, Richardson P, Chauhan D et al (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61(7):3071–3076

    PubMed  CAS  Google Scholar 

  9. Adams J (2001) Proteasome inhibition in cancer: development of PS-341. Semin Oncol 28(6):613–619

    Article  PubMed  CAS  Google Scholar 

  10. Richardson PG, Sonneveld P, Schuster MW et al (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352(24):2487–2498

    Article  PubMed  CAS  Google Scholar 

  11. Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J (1999) The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 5(9):2638–2645

    PubMed  CAS  Google Scholar 

  12. Nawrocki ST, Bruns CJ, Harbison MT et al (2002) Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 1(14):1243–1253

    PubMed  CAS  Google Scholar 

  13. Cusack JC Jr, Liu R, Houston M et al (2001) Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 61(9):3535–3540

    PubMed  CAS  Google Scholar 

  14. Orlowski RZ, Stinchcombe TE, Mitchell BS et al (2002) Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20(22):4420–4427

    Article  PubMed  CAS  Google Scholar 

  15. Aghajanian C, Soignet S, Dizon DS et al (2002) A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 8(8):2505–2511

    PubMed  CAS  Google Scholar 

  16. Adams J, Palombella VJ, Sausville EA et al (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59(11):2615–2622

    PubMed  CAS  Google Scholar 

  17. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205–216

    Article  PubMed  CAS  Google Scholar 

  18. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10(1):1–10

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Supported by N01 CM 17107 to Princess Margaret Hospital and U01 CA69852-08 to the University of Chicago.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Malcolm J. Moore.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gomez-Abuin, G., Winquist, E., Stadler, W.M. et al. A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia. Invest New Drugs 25, 181–185 (2007). https://doi.org/10.1007/s10637-006-9009-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-006-9009-4

Keywords

Navigation